期刊文献+

术中恶性高热成功抢救一例

下载PDF
导出
摘要 恶性高热(malignant hyperthermia,MH)较为罕见,是目前所知的唯一可由常规麻醉用药引起围手术期死亡的遗传性疾病。其是一种亚临床肌肉病,即患者平时无异常表现,多表现为吸入强效全身麻醉药及去极化肌松药琥珀酰胆碱后诱发的骨骼肌高代谢综合征,术前不易诊断,在无特异性治疗药物的情况下,可致患者死亡,病死率极高。儿童发病率为1/30~50万,成人为1,5~10万。本院1例特发性脊柱侧弯患者,在全身麻醉下(七氟烷)行脊柱侧弯矫形内固定术,术中发生MH,并出现检验危急值,最终救治成功。现报道如下。
作者 郑英 李杨
出处 《浙江临床医学》 2018年第3期563-564,共2页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献5

二级参考文献76

  • 1王颖林,郭向阳,罗爱伦.恶性高热诊断和治疗的研究进展[J].中华麻醉学杂志,2006,26(1):92-94. 被引量:22
  • 2王颖林,郭向阳,罗爱伦.我国大陆恶性高热病例的分析[J].中华麻醉学杂志,2006,26(2):107-109. 被引量:45
  • 3车昊,张亚军,贾乃光,李成辉.药源性恶性高热的临床表现与治疗[J].中日友好医院学报,2006,20(2):119-121. 被引量:5
  • 4Mitchell LW,Leighton BL.Wanned diluent speeds dantrolene reconst-itution.Can J Anaesth,2003,50(2):127-130.
  • 5Podranski T,Bouillon T,Schumacher PM,et al.Compartmental pharmacoki-netics of dantrolene in adults:do malignant hyperthermia association dosing guidelines work? Anesth Analg,2005,101(6):1695-1699.
  • 6Paul-Pletzer K,Palnitkar SS,Jimenez LS,et al.The skeletal muscle ryanedine receptor identified as a molecular target of[3H]azidudantrolene by photoaffinity labeling.Biochemistry,2001,40 (2):531-542.
  • 7Palnitkar SS,Mickelson JR,louis CF,et al.Pharmacological distinction between dantrolene and ryanodine binding sites:evidence from normal and malignant hyperthermia-suseeptible porcine skeletal muscle.Biochemical Journal,1997,326(pt3):847-852.
  • 8Aleman M,Riehl J,Aldridge BM,et al.Association of a mutation in the ryanodine receptor I gene with equine malignant hyperthermia.Muscle Nerve,2004,30(3):356-365.
  • 9Robinson RL,Curran JL,Ellis FR,et al.Multiple interacting gene pro-ducts may influence susceptibility to malignant hyperthermia.Ann Hum Genet,2000,64(pt4):307-320.
  • 10Sambuughin N,Holley H,Muldoon S,et al.Screening of the entire ryanedine receptor type 1 ceding region for sequence variants associated with ma-lignant hyperthermia susceptibility in the North American population.Anesthesiology,2005,102(3):515-521.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部